Page 4 - ஒழுங்குமுறை சிகிச்சை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Regulus Therapeutics Announces Completion of Dosing in the First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) News provided by Share this article LA JOLLA, Calif., April 15, 2021 /PRNewswire/  Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the Company or Regulus ), today announced that it completed dosing in the first cohort of nine patients with ADPKD in its Phase 1b clinical trial of RGLS4326. The study is evaluating the safety, pharmacokinetics, and biomarkers (polycystin 1 (PC1) and polycystin 2 (PC2)) of multiple doses of RGLS4326 in patients with ADPKD.

Jay haganExchange commissionRnas the company or regulusRegulus therapeutics incRegulus therapeuticsPartial clinical holdPrivate securities litigation reform actஜெய் ஹகன்பரிமாற்றம் தரகுஒழுங்குமுறை சிகிச்சை இன்க்ஒழுங்குமுறை சிகிச்சைபகுதி மருத்துவ பிடிப்ரைவேட் பத்திரங்கள் வழக்கு சீர்திருத்தம் நாடகம்